Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Will Pfizer's Potential Acquisition of Medivation Result in Lower Costs for Xtandi?

XTALKS VITALS NEWS

Drug

The Pfizer acquisition is expected to be completed before 2017.

Share this!

September 16, 2016 | by Kelly Daescu

One sign of prostate cancer is increased androgen expression, and therefore a common prostate cancer treatment is androgen-deprivation therapy. While androgen-deprivation therapy is effective in many cases, aggressive cancers can become resistant because basal levels of androgen remain circulating in the body, and over time, cancer cells can thrive just on these small levels alone. XTandi is a second tier attack used for prostate cancer that has become resistant to androgen deprivation. It works by preventing receptors from recognizing their androgen ligand. Xtandi has been found to successfully improve survival in metastatic prostate cancer patients.

Xtandi, unfortunately, comes with a price tag upwards of $100,000 a year. This has raised some eyebrows, and pressure is mounting for the right for other drug companies to compete so that prices decrease. The argument is that the R&D of Xtandi was completed at a public university with public funds, and indeed, UCLA created the drug and sold it to Medivation in 2005.

The government denied release of drug rights, keeping Medivation’s monopoly and exclusivity. The position of power that the government’s support would seemingly place Medivation in, has been tenuous. In April, the French pharmaceutical giant Sanofi made a bid of $9.3 billion, although their bid came with a bit of strong-arming and threats to Medivation’s board of directors. This initial offer was the catalyst for Medivation opening up several confidentiality agreements, inviting multiple potential suitors to “get to know” the company prior to making an offer. Several companies, in addition to Sanofi, were also interested, but it was announced last month that Pfizer, with its hefty bid of nearly $14 billion, won the prize. One small Canadian company has even offered the production of the drug for just $3 per tablet down from $88, but has been, so far, unable to obtain NIH approval since the drug is likely to remain widely available. Pending an antitrust review, the Pfizer acquisition is expected to be completed before 2017. So far, there has been no indication that this will result in a price drop.


Keywords: Acquisition, Prostate cancer


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.